Skip to main content

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SRPT, TXT and TME

NEW YORK, NY / ACCESSWIRE / October 11, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
Class Period: September 6, 2017 to August 19, 2019
Lead Plaintiff Deadline: October 29, 2019

The lawsuit alleges Sarepta Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen's accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in SRPT: http://www.kleinstocklaw.com/pslra-1/sarepta-therapeutics-inc-loss-submission-form?id=3928&from=1

Textron Inc. (NYSE: TXT)
Class Period: January 31, 2018 to October 17, 2018
Lead Plaintiff Deadline: October 21, 2019

Throughout the class period, Textron Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) end market sales of Arctic Cat products were slowing, resulting in a massive glut of old Arctic Cat inventory on dealers' floors; (2) in order to clear out this old inventory, the Company provided significant price discounts, which negatively impacted Textron's earnings; and (3) as a result, Textron's positive statements about Arctic Cat's business, operations, and prospects lacked a reasonable basis.

Learn about your recoverable losses in TXT: http://www.kleinstocklaw.com/pslra-1/textron-inc-loss-submission-form?id=3928&from=1

Tencent Music Entertainment Group (NYSE: TME)
Class Period: December 12, 2018 to August 26, 2019
Lead Plaintiff Deadline: November 25, 2019

The complaint alleges that during the class period Tencent Music Entertainment Group made materially false and/or misleading statements and/or failed to disclose that: (1) Tencent Music's exclusive licensing arrangements with major record labels were anticompetitive; (2) consequently, sublicensing such content from Tencent Music was unreasonably expensive, in violation of Chinese antimonopoly laws; (3) these anticompetitive efforts were reasonably likely to lead to regulatory scrutiny; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in TME: http://www.kleinstocklaw.com/pslra-1/tencent-music-entertainment-group-loss-submission-form?id=3928&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/562878/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-SRPT-TXT-and-TME

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.